Amgen increases share buyback programme by $5 billion
This article was originally published in Scrip
Amgen's board of directors has authorised an expansion of the company's share buyback programme by $5 billion. It also has $1.2 billion remaining under a previous stock repurchase programme. The company said the move reflected its confidence in its long-term prospects.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.